Advocates have long argued that marijuana legalization is a superior alternative to criminalization. But while that sentiment prevails with the public and a growing number of lammakers, a leading drug policy reform group says it’s nonetheless important to recognize and address potential public health impacts of consumer trends in state-regulated markets—including the rise of high-potency THC products.
Prohibitionists have been quick to seize upon reports of adverse health incidents associated with products engineered to maximize THC, whether it’s naturally produced delta-9 THC in marijuana, synthetically manufactured delta-8 THC in hemp or any of the numerous other iterations of the intoxicating cannabinoid.
But rather than revert to banning such products outright, officials should prioritize targeted regulations to balance public health and consumer choice, the pro-legalization Drug Policy Alliance (DPA) said in a new report titled “High-THC Marijuana: Protecting Public Health In A Changing Market.”
“As product potency rises, so do important public health questions about safety, youth access, and consumer transparency,” it says, adding that DPA’s position is that “legalization must be paired with thoughtful, evidence-based regulation that protects health, enhances safety, and reduces harm.”
The organization isn’t necessarily arguing that high-THC cannabis products present an imminent public health threat, pointing to the “mixed body of research” on the potential negative health impacts such as the development of cannabis use disorder, anxiety and other mental health conditions. But there is a need to expand research into the issue and inform public policy, particularly as it concerns youth use and access, DPA said.
For some patients, higher concentrations of THC can “help manage pain and other medical conditions,” the report said, so regulations should “consider medical exemptions or alternate provisions to accommodate these patients’ needs.” At the same time, one of the group’s recommendations is to ensure that legal markets offer a diversified array of products that includes low-THC options for patients and consumers.
Overall, one of DPA’s top recommendations is to create a “unified regulatory framework for all cannabinoids (including hemp-derived products like delta-8 THC) with consistent standards for testing, labeling, age restrictions, and consumer protections.”
Other proposals essentially follow the same line of policy thinking that reform advocates have long pushed for as an alternative to criminalizing cannabis. That is, they want to see research (including opportunities for federal studies) expanded, restrictions such as age-gating enforced to mitigate youth access and tax revenue allocations that support mental health treatment and other public health initiatives.
There should also be improvements in “consumer education and product transparency with standardized serving sizes, clear THC content labeling, prominent warning labels, retail education materials, and training for dispensary staff,” the report says.
Because there may be health impacts associated with high-THC cannabis, policymakers should additionally consider potential alternatives to blanket bans that still aim to steer the market away from becoming oversaturated with such products. That could include setting prices based in part on THC potency, while also requiring low-THC product availability in the regulated market.
Although the science and health impacts of high-THC cannabis is still being studied, one thing is undeniable: There has been a steady rise in the marketing and sale of such products as the state legalization movement has expanded and businesses have responded to consumer demand. DPA’s report is meant to respond to that reality, without ceding the issue to anti-legalization interests that have used fears about the use of these highly potent products to promote prohibitionist policies.
Cat Packer, DPA’s director of legal regulation, said in a Q&A about the THC potency issue that “no one should be arrested for marijuana and policies cannot return to bringing back harmful and ineffective criminalization tactics.”
“Legal regulation must address the ongoing harms of criminalization that impede on someone’s livelihood and basic needs,” she said. “At minimum, clearing records for all past marijuana arrests and convictions. Not having a criminal record removes barriers to economic opportunities and housing access. Ending criminalization also stops law enforcement from targeting certain communities.”
The DPA report concludes by reiterating that high-THC marijuana products “pose complex regulatory challenges that demand a balanced, evidence-based response.”
“As product potency increases and markets evolve, policy must keep pace. Failing to modernize regulatory frameworks poses threats to public health, particularly for youth and individuals vulnerable to mental and physical health issues and substance use disorders,” it says.
“By aligning hemp and marijuana regulations, strengthening research and data collection, improving product transparency, and implementing safeguards for high-THC products, policymakers can reduce preventable harms while preserving access for adult consumers and medical patients,” it continues. “Public education, responsible retail practices, and reinvestment of tax revenue into treatment and prevention are critical to regulation that balances commercial interests with public health.”
Aligning hemp and marijuana rules has become all the more urgently needed as the federal definition of hemp is set to fundamentally change later this year, with a significantly more restrictive threshold for THC to be considered legal hemp. Industry stakeholders say that policy change, which is set to take effect in November under a broader agriculture law President Donald Trump enacted last year, threatens to effectively eradicate the consumable cannabinoid market.
“A strong regulatory framework that is grounded in evidence, health, and consumer protections offers the clearest path forward,” DPA said. “Policymakers should heed these recommendations to mitigate risks, promote informed decision-making, and ensure market innovations do not outpace health protections.”
Meanwhile, amid shifting state and federal cannabis policies, the White House has scheduled several meetings with cannabis industry and research stakeholders to discuss a proposed enforcement policy for non-intoxicating CBD products.
Also in the background, advocates and stakeholders are also eagerly awaiting the finalization of a rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). Trump signed an executive order in December directing the attorney general to expeditiously complete that process—which would help streamline cannabis research while allowing state-licensed businesses to take federal tax deductions—but that remains pending.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
